BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) — Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases, today announced that on October 9, 2017 the Company granted Jeffrey Hatfield…
Source: BioSpace